60575-19-1

Usage

Uses

Used in Pharmaceutical Research and Development:
CHROMAN-3-YLAMINE is used as a building block for the synthesis of biologically active molecules due to its versatile chemical structure and potential to contribute to the development of new drugs.
Used in Medicinal Chemistry:
CHROMAN-3-YLAMINE is utilized as a key component in the design and synthesis of pharmaceutical compounds, particularly those with anti-inflammatory and antitumor properties, owing to its pharmacological activity.
Used in Drug Discovery:
As a compound with demonstrated potential in medicinal chemistry, CHROMAN-3-YLAMINE is used in drug discovery processes to identify and develop new therapeutic agents with improved efficacy and safety profiles.

InChI:InChI=1/C9H11NO/c10-8-5-7-3-1-2-4-9(7)11-6-8/h1-4,8H,5-6,10H2

Upstream product

• 18518-71-3 3-aminochroman hydrochloride 
• 19090-04-1 chroman-3-one 
• 22649-28-1 2H-chromene-3-carboxylic acid 
• 57543-66-5 2H-chromene-3-carbonitrile 
• 90-02-8 salicylaldehyde 
• 1034770-39-2 chroman-3-one O-methyl oxime 
• 92210-53-2 3-nitro-2H-1-benzopyran 
• 153167-33-0 3-nitro-3,4-dihydro-2H-1-benzopyrane 

Relevant academic research and scientific papers

POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF

Certain aspects of the invention relate to small molecule autophagy inhibitors, and their use for treatment and prevention of cancers and acute pancreatitis. Medicinal chemistry studies led to small molecular autophagy inhibitors with improved potency and selectivity.

ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

Centrally acting 6,7,8,9-tetrahydro-3H-benz(E)indole heterocyclics

A compound of Formula I STR1 or pharmaceutically acceptable salts of Formula I, where R1 is H, C1 -C3 alkyl, --(CH2)n CONH2 where n is 2 to 6, (CH2)n -1-(4,4-dimethylpiperidine-2

3,4-Dihydro-3-amino-2H-1-benzopyran Derivatives as 5-HT1A Receptor Ligands and Potential Anxiolytic Agents. 1. Synthesis and Structure-Activity Relationship Studies

A series of 3,4-dihydro-3-amino-2H-1-benzopyran derivatives were prepared in order to determine the necessary structural requirements for good affinity for 5-HT1A receptors and high selectivity versus other receptors.Modifications of the extrac

Centrally acting 6,7,8,9-tetrahydro-3H-benz(e)indole heterocyclics

A compound of Formula I STR1 or pharmaceutically acceptable salts of Formula I, where R 1 is H, C 1 -C 3 alkyl, --(CH 2) n CONH 2 where n is 2 to 6, (CH2) n -1-(4,4-dimethylpiperidine-2,6-dione-yl), or cyclopropylmethyl;R 2 is hydrogen, C 1 -C 8 alkyl, C